Biotech News
Related news
ABOSAcumen Pharmaceuticals2026-10-19 20:00 EST
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
ABOSAcumen Pharmaceuticals2026-08-12 11:00 EST
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
TNXPTonix Pharmaceuticals2026-08-10 11:00 EST
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
NBIXNeurocrine Biosciences2026-10-12 20:01 EST
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
TEVATeva Pharmaceutical Industries2026-09-23 20:45 EST
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
XERSXeris Pharmaceuticals2026-10-22 12:00 EST
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
ALKSAlkermes plc2026-10-20 20:00 EST
Alkermes to Report Third Quarter Financial Results on November 3, 2026
HRMYHarmony Biosciences2026-10-20 12:05 EST
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
AXSMAxsome2026-10-07 11:00 EST
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
ADXNAddex Therapeutics2026-09-24 05:00 EST
Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
Supernus
CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...
Recent company news
SUPNSupernus2026-10-21 23:45 EST
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
SUPNSupernus2026-10-19 12:30 EST
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
SUPNSupernus2026-09-02 20:30 EST
Supernus Pharmaceuticals to Participate in September Investor Conferences
SUPNSupernus2026-08-31 12:30 EST
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
SUPNSupernus2026-08-03 10:35 EST
Supernus Announces Second Quarter 2026 Financial Results
Stock data
- Close
- 41.21 USD
- Market cap
- 2.56B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States